RxDoctor Payments Data

Shawn Hamm, MD

Addiction Medicine · Bartlett, TNNPI 1821330895

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Indivior Inc. at 37.8% of the total. 2025 is the largest year on record at $649, 4.3 times the $153 reported in 2019.

$2,048in general payments, 2019–2025

Across 100 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$775
  • Braeburn Inc.$640
  • Alkermes, Inc.$280
  • MDD US Operations, LLC$98
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$79
  • AbbVie$53
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$2,02499%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,048 in reported general payments places this provider in the 85th percentile of 76 addiction medicine providers in Tennessee.

See all addiction medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,168
Medicare patients
58
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl1,132$184,033
BrixadiBuprenorphine25$40,044
SuboxoneBuprenorphine Hcl/Naloxone Hcl56$39,798
TrintellixVortioxetine Hydrobromide15$7,195
Varenicline Tartrate28$6,337
Duloxetine Hcl52$1,630
Gabapentin147$1,420
Hydroxyzine Hcl118$1,389
Acamprosate Calcium14$1,026
Pregabalin17$758
Quetiapine Fumarate56$686
Clonazepam109$550
Clonidine Hcl ErClonidine Hcl11$483
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$467
Buspirone Hcl31$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braeburn Inc.Brixadi$640$40,04425 claims
Indivior Inc.Suboxone$775$39,79856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 76 addiction medicine providers in Tennessee.

Other addiction medicine in Bartlett

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →